What’s New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

DOI Web Site 被引用文献2件
  • Giuseppe Tirino
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Luca Pompella
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Angelica Petrillo
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Maria Maddalena Laterza
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Annalisa Pappalardo
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Marianna Caterino
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Michele Orditura
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Fortunato Ciardiello
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Gennaro Galizia
    Division of GI Tract Surgical Oncology, Department of Cardio-Thoracic and Respiratory Sciences, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
  • Ferdinando De Vita
    Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy

説明

<jats:p>Despite some remarkable innovations and the advent of novel molecular classifications the prognosis of patients with advanced gastric cancer (GC) remains overall poor and current clinical application of new advances is disappointing. During the last years only Trastuzumab and Ramucirumab have been approved and currently used as standard of care targeted therapies, but the systemic management of advanced disease did not radically change in contrast with the high number of molecular drivers identified. The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) classifications paved the way, also for GC, to that more contemporary therapeutic approach called “precision medicine” even if tumor heterogeneity and a complex genetic landscape still represent a strong barrier. The identification of specific cancer subgroups is also making possible a better selection of patients that are most likely to respond to immunotherapy. This review aims to critically overview the available molecular classifications summarizing the main druggable molecular drivers and their possible therapeutic implications also taking advantage of new technologies and acquisitions.</jats:p>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ